Compare Viatris Inc (VTRS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Viatris Inc trades at $17.58 (market cap $19.79B), while State Street SPDR S&P Biotech ETF trades at $154.42. The key difference: Viatris Inc pays a 2.83% dividend while State Street SPDR S&P Biotech ETF pays none, and Viatris Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| VTRS | XBI | |
|---|---|---|
Market Cap | $19.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $17.39 | $164.28 |
52-Week Low | $8.74 | $85.16 |
Enterprise Value | $32.00B | — |
Dividend Yield | 2.83% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
